SLNSilence Therapeutics Plc American Depository Share

ADRCNasdaq (XNAS)·USD

Identity

Security key: 21709
Ticker: SLN
Type: ADRC — American Depository Receipt Common
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2020-09-08
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: SLN

Detail

Enriched 2026-08-14 20:47

Market cap: $641,446,044.54
Shares outstanding (class): 47,234,613
Shares outstanding (weighted): 47,234,613
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 88
Location: LONDON
Homepage: https://www.silence-therapeutics.com
Description: Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Market cap and share counts drift.

Funds holding this security

4 funds · 4 positions · $968.5K reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
iShares Biotechnology ETF iShares Trust	IBB	$913.4K	0.01%	173,313 NS	FIGI
State Street(R) SPDR(R) S&P(R) International Sm… SPDR INDEX SHARES FUNDS	GWX	$49.7K	0.01%	9,434 NS	FIGI
Blackstone Alternative Multi-Strategy Fund Blackstone Alternative Investment Funds	—	$5.3K	0.00%	1,000 NS	FIGI
College Retirement Equities Fund - Total Global… College Retirement Equities Fund	—	$126.48	0.00%	24 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERSLN
FIGI_COMPOSITEBBG00WVTHPN2
FIGI_SHARE_CLASSBBG00WVTHQK3
CIK0001479615
ISINUS82686Q1013
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.9
Model: deepseek
Rationale: Silence Therapeutics is a biopharmaceutical company developing RNAi therapeutics, classified under healthcare/biotechnology.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.